Nalini kanta Sahoo
DOI: JBABM.2020.12
Without continual growth and progress, such words as improvement, achievement, and success have no meaning. Journal of Bioanalysis & Biomedicine (ISSN: 1948-593X) is growing continuously. It is our pleasure to announce that during year 2020, all issues of volume 12 were published online on time and the print issues were also brought out and dispatched within 30 days of publishing the issue online.
All published articles of this journal are included in the indexing and abstracting coverage of CAS Source Index (CASSI), Index Copernicus, Google Scholar, Sherpa Romeo, RefSeek, China National Knowledge Infrastructure (CNKI), Directory of Research Journal Indexing (DRJI), Hamdard University, EBSCO A-Z, OCLC- WorldCat, SWB online catalog, Publons, Authors having NIH grant were submitted to PubMed (PubMed NLM ID: 101550236).
During the calendar year 2019, JBABM received a total of 21 papers, out of which 6 articles were rejected in the preliminary screening due to plagiarism or being out of the format and peer review process. During 2019 around 10 articles were subjected for publication after they are accepted in the peer review process. In the 6 issues of Volume 11 published during the year 2019, a total of 10 articles were published (at an average of 2 articles per issue) of which, articles were published from authors all around the world. A total of 50 research scientists from all over the world reviewed the 10 articles published in volume 11. Average publication lag time of an article was further reduced to 2-3 weeks.
Journal of Bioanalysis & Biomedicine also announces its new association with Hilaris Publishing group for Archiving, Journal maintenance, financial purpose and support. Journal will be running its website https://www.hilarispublisher.com/bioanalysis- biomedicine.html parallel for Editorial and review work process so as to maintain its highest standard of scientific work.
Association with Hilaris Publishing Group has increased Readership Metrics (By Google Analytics) of Journal of Bioanalysis & Biomedicine at the same.
I take this opportunity to acknowledge the contribution of Editor-in- Chief: Dr. Alexey Goltsov (UK) and Dr. Carl K Edwards during the final editing of articles published and the support rendered by the editorial assistant in bringing out issues of JBABM in time. I would also like to express my gratitude to all the authors, reviewers, the publisher, the advisory and the editorial board of JBABM, the office bearers for their support in bringing out yet another volume of JBABM and look forward to their unrelenting support to bring out the Volume 12 of JBABM in scheduled time.
Xiaolong Zhang, Linglong Zou, Weiping Shao and Zhongping Lin, et al.
DOI: 10.37421/jbabms.2020.12.227
Over the past ten years, the global market for large molecule therapeutics has rapidly grown for the treatment of a variety of diseases. LBA and LC-MS are two platforms widely used in pharmacokinetic bioanalysis. In this paper, we compare LBA and LC-MS and summarize their strengths and limitations. Strategies for platform selection are provided according to the study purpose, study phase, analyte types, assay requirements and other factors.
